Skip to main content

Table 2 Adjusted mean difference from baseline (mean) and standard error (SE) of total cholesterol (TC), LDL-cholesterol (LDL), total cholesterol/HDL-cholesterol ratio (TC/HDL) and triglycerides (TG) one year after the switch

From: Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA)

Switch TC T2 - TC T0
(mg/dl)
LDL T2 - LDL T0
(mg/dl)
HDL T2 - HDL T0
(mg/dl)
TC/HDL T2 - TC/HDL T0
(mg/dl)
TG T2 - TG T0
(mg/dl)
FRS T2 - FRS T0
From To mean (±SE) p* mean (±SE) p* mean (±SE) p* mean (±SE) p* mean (±SE) p* mean (±SE)
2 NRTI + EFV DTG −15.0 ± 6.5 .0210 − 10.9 ± 6.2 .0771 −1.4 ± 1.8 .4222 − 0.21 ± 0.21 .3242 − 19.6 ± 15.2 .1992 0.67 ± 0.71 0.35
EVG 1.7 ± 8.6 .8401 − 5.9 ± 8.0 .4623 2.8 ± 2.4 .2350 − 0.32 ± 0.27 .2488 27.2 ± 20.5 .1853 0.74 ± 0.92 0.42
RPV −31.6 ± 5.3 <.0001 −21.0 ± 5.0 <.0001 − 2.9 ± 1.4 .0421 − 0.52 ± 0.17 .0021 −31.5 ± 12.4 .0116 0.03 ± 0.38 0.93
2 NRTI + PI/r DTG −16.8 ± 5.9 .0049 −8.8 ± 5.7 .1247 2.4 ± 1.6 .1335 − 0.60 ± 0.19 .0015 −26.1 ± 14.0 .0628 − 0.54 ± 0.60 0.36
EVG −16.6 ± 5.8 .0044 − 12.0 ± 5.6 .0312 3.0 ± 1.6 .0604 − 0.63 ± 0.18 .0007 −23.0 ± 16.6 .0926 −0.87 ± 0.52 0.10
RPV − 20.7 ± 5.2 <.0001 −13.6 ± 5.0 .0064 0.00 ± 1.4 .9995 − 0.52 ± 0.17 .0021 − 28.2 ± 12.2 .0216 −0.25 ± 0.48 0.60
  1. NRTI nucleoside reverse transcriptase inhibitors; EFV efavirenz, PI/r ritonavir-boosted protease inhibitors, DTG dolutegravir, EVG elvitegravir, RPV rilpivirine, T0 baseline, T2 one year follow up. Significant p values (p < 0.05) are indicated by bold font
  2. *Adjustment for age, sex, baseline value of the analyzed variable, time on antiretroviral therapy, diabetes and use of statin
  3. § Adjustment for baseline value of FRS and time on antiretroviral therapy